Roger himself has stated the following, and that time has arrived.
“In our view, the start and completion of the ‘first in man’ study of PPL1 will provide significant upside as it will open the doors for major cancer applications with large pharmaceutical companies. This should see our investors rewarded for helping us through the challenging early phase of the drug’s life.”
